Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA

Today, Ultragenyx Pharmaceuticals shared a press release announcing a “Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program.” 

Read the full press release. 

 Livestream Update on Wednesday, July 24

Tune into the LIVESTREAM updates at the ASF Family Conference on Wednesday at 3:10pm ET. 

To access the link, visit the conference agenda and select Day 2.